SyntheX

📍 San Francisco, United States🗓 Founded 2016👥 21 employees💰 Last funded Sep 2017
Biotechnology Research🌐 SyntheXlabs.com
Website LinkedIn
SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner. Our lead programs focus on oncology.
4
Total investors
4
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2016–2017 · investors recorded per year
2016120173
Recent (last 2y)Earlier
Frequently asked questions
Who invested in SyntheX?
SyntheX has 4 investors on record on gritt.io, including 4 early-stage backers.
When did SyntheX last raise funding?
The most recent investment in SyntheX recorded on gritt.io was in September 2017.
When was SyntheX founded?
SyntheX was founded in 2016.
What industry is SyntheX in?
SyntheX operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SyntheX based?
SyntheX is headquartered in San Francisco, United States.